Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer

Expert Opinion on Biological Therapy

Volumn 14, Issue 1, 2014, Pages 7-10

  Dellis, Athanasios ^a,b   Papatsoris, Athanasios G ^a,c,d  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Hellenic Genito Urinary Cancer Group   (Greece)

^d Institute of Molecular Medicine and Biomedical Research   (Greece)

Author keywords

Castration; Denosumab; Prostate cancer; Skeletal metastases

Indexed keywords

ABIRATERONE; CABAZITAXEL; DENOSUMAB; ENZALUTAMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; SIPULEUCEL T; ZOLEDRONIC ACID;

BONE DENSITY; BONE DESTRUCTION; BONE METASTASIS; BONE REMODELING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL MATURATION; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; DRUG SAFETY; HEALTH CARE QUALITY; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FUNCTION; MOUTH HYGIENE; MULTIPLE MYELOMA; OBSTRUCTIVE UROPATHY; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; PAIN; POSTMENOPAUSE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RISK FACTOR; TOOTH EXTRACTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; HUMANS; IMIDAZOLES; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

EID: 84890137252     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.840582     Document Type: Review

References (22)

1. Fizazi K. Nonhormone therapy for metastatic castration-resistant prostate cancer. Soc Clin Oncol Educ Book 2013;2013:161-5
2. Papatsoris AG, Karamouzis MV, Papavassiliou AG. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Curr Med Chem 2005;12(3):277-96
3. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant non-metastatic prostate cancer. Cancer 2011;117(10):2077-85
4. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. In European Association of Urology (EAU) Guidelines, edition presented at the 28th Annual EAU Congress, Milan; 2013
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423(6937):337-42
6. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011;48(4):677-92
7. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008;25(2):119-29
8. Gartrell BA, Coleman RE, Fizazi K, et al. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kB ligand inhibitors in patients with advanced prostate cancer. Eur Urol 2013; Epub ahead of print
9. Qi WX, Tang LN, He AN, et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 2013; Epub ahead of print
10. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2010;103:232-40
11. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27(32):5356-62
12. van Poznak CH, Temin S, Yee GC, et al. ASCO Clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. JCO 2001;29(9):1221-7
13. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361(8):745-55
14. Smith MR, Saad F, Coleman R, et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: Results of a global phase 3, randomised, placebo-controlled trial. Lancet 2012;379(9810):39-46
15. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat.Rev 2013;39(1):97-104
16. Parker C, Nilsson S, Heinrich D, et al. Alpha Emiter Radium-223 and survival in metastatic prostate cancer. NEJM 2013;369(3):213-23
17. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 2011;377(9768):813-22
18. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48(16):3082-92
19. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12(4):1221-18
20. Ford J, Cummins E, Sharma P, et al. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technol Assess 2013;17(29):1-386
21. Snedecor SJ, Carter JA, Kaura S, Botteman MF. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectivenessanalysis. J Med Econ 2013;16(1):19-29
22. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. In European Association of Urology (EAU) Guidelines, edition presented at the 28th EAU Annual Congress, Milan; 2013